Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitour...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for prior...
Bristol Myers Squibb (NYSE: BMY) announced results of an analysis from the three-arm Phase 3 CheckMate -8HW trial evaluating Opdivo® (ni...
Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...
AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...
Antennova, a clinical-stage biotech company focused on oncology announced the presentation of latest data from its Phase I/II CLINCH s...
Kite, a Gilead Company (Nasdaq: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axica...
Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines fo...
Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CA...
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, announced its innovative drug development strategy in the rigorous and cutti...
© 2025 Biopharma Boardroom. All Rights Reserved.
